Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Drug Fees In, DTC Fees Dropped, From Obama Budget Proposal

Executive Summary

Some of FDA's funding increase promised in President Obama's budget comes from user fees which would have to be established legislatively - meaning that the administration will have to negotiate with industry and congressional authorizing committees, not just House and Senate appropriators, in order to see its vision enacted

You may also be interested in...



FDA Budget Enhances Safety Programs, But Relies On Theoretical User Fees

FDA proposes to increase its medical product safety spending by $100.8 million in the fiscal 2011 budget submitted to Congress Feb. 1

FDA Budget Enhances Safety Programs, But Relies On Theoretical User Fees

FDA proposes to increase its medical product safety spending by $100.8 million in the fiscal 2011 budget submitted to Congress Feb. 1

FDA Appropriations In Senate: Money For Generics; Worry About Tobacco

Senate appropriators would like to see FDA spend $93 million in fiscal year 2010 on its generic drugs program

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel